DCLK1, as the most potential colorectal cancer stem cell (CSC) marker has been the core of many recent investigations. However, no study has been performed to evaluate the circulating cellular DCLK1 protein (CCDP) that might reflect the presences of colorectal CSC in circulation.
OBJECTIVES:
We aimed to evaluate CCDP in the peripheral blood mononuclear cells (PBMCs) of colorectal cancer (CRC) patients applying immunoassay based methods including PLA, IPCR and ELISA in order to introduce the method of choice for clinical detection of CCDP.
METHODS:
PBMCs were extracted from blood samples of 58 CRC patients along with 58 blood samples of tumor free controls. Total protein of PBMC was extracted and the CCDP level was evaluated. The results of three applied immunoassay tests were compared and the best approach for clinical application was introduced, accordingly. In addition, the correlation of CCD Plevel with clincopathologic findings of CRC patients was assessed.
RESULTS:
The results of three immuneassay methods confirmed each other. Based on our finding, ELISA could be the most judicious method for clinical evaluation of CCDP considering its simplicity for clinical implications. Our results also showed a significant higher amount of CCDP in peripheral blood of CRC patients compared to control group which was also correlated with patients' clinicopathologic finding such as stage, grade and neoadjuvant history.
CONCLUSION:
CCDP could be applied for monitoring purposes in CRC patients. However, its application needs to be more elucidated in future investigations implementing larger samples.
ReyaT., MorrisonS.J., ClarkeM.F. and WeissmanI.L., Stem cells, cancer, and cancer stem cells, Nature414 (2001), 105-111.
2.
PardalR., ClarkeM.F. and MorrisonS.J., Applying the principles of stem-cell biology to cancer, Nature Reviews Cancer3 (2003), 895-902.
3.
DalerbaP., ChoR.W. and ClarkeM.F., Cancer stem cells: models and concepts, Annu. Rev. Med.58 (2007), 267-284.
4.
YangZ.F., NgaiP., HoD.W., YuW.C., NgM.N., LauC.K., LiM.L., TamK.H., LamC.T. and PoonR.T., Identification of local and circulating cancer stem cells in human liver cancer, Hepatology47 (2008), 919-928.
5.
IinumaH., WatanabeT., MimoriK., AdachiM., HayashiN., TamuraJ., MatsudaK., FukushimaR., OkinagaK. and SasakoM., Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes' stage B and C colorectal cancer, Journal of Clinical Oncology29 (2011), 1547-1555.
6.
KantaraC., O'ConnellM.R., LuthraG., GajjarA., SarkarS., UllrichR.L. and SinghP., Methods for detecting circulating cancer stem cells (CCSCs) as a novel approach for diagnosis of colon cancer relapse/metastasis, Laboratory Investigation (2014).
7.
ScatenaR., BottoniP. and GiardinaB., Circulating tumour cells and cancer stem cells: a role for proteomics in defining the interrelationships between function, phenotype and differentiation with potential clinical applications, Biochimica et Biophysica Acta (BBA)-Reviews on Cancer1835 (2013), 129-143.
8.
ParkB.S., JungS.Y., KwonS.M., BaeJ.H., LeeS.M., ShinD.H. and SonG.M., Comparison of putative circulating cancer stem cell detection between the hepatic portal system and peripheral blood in colorectal cancer patients, Annals of Surgical Treatment and Research87 (2014), 232-238.
9.
ChibaT., KanaiF., IwamaA. and YokosukaO., Circulating cancer stem cells: A novel prognostic predictor of hepatocellular carcinoma, Hepatobiliary Surgery and Nutrition2 (2013), 4.
10.
TangD.G., Understanding cancer stem cell heterogeneity and plasticity, Cell Research22 (2012), 457-472.
11.
SchattonT., MurphyG.F., FrankN.Y., YamauraK., Waaga-GasserA.M., GasserM., ZhanQ., JordanS., DuncanL.M. and WeishauptC., Identification of cells initiating human melanomas, Nature451 (2008), 345-349.
12.
QuintanaE., ShackletonM., SabelM.S., FullenD.R., JohnsonT.M. and MorrisonS.J., Efficient tumour formation by single human melanoma cells, Nature456 (2008), 593-598.
13.
BaiocchiM., BiffoniM., Ricci-VitianiL., PilozziE. and De MariaR., New models for cancer research: human cancer stem cell xenografts, Current Opinion in Pharmacology10 (2010), 380-384.
14.
dos SantosR.V. and da SilvaL.M., A possible explanation for the variable frequencies of cancer stem cells in tumors, PloS One8 (2013), e69131.
15.
dos SantosR.V. and da SilvaL.M., The noise and the KISS in the cancer stem cells niche, Journal of Theoretical Biology335 (2013), 79-87.
16.
NakanishiY., SenoH., FukuokaA., UeoT., YamagaY., MarunoT., NakanishiN., KandaK., KomekadoH. and KawadaM., Dclk1 distinguishes between tumor and normal stem cells in the intestine, Nature Genetics45 (2013), 98-103.
17.
ShuT., TsengH.-C., SapirT., SternP., ZhouY., SanadaK., FischerA., CoquelleF.M., ReinerO. and TsaiL.-H., Doublecortin-like kinase controls neurogenesis by regulating mitotic spindles and M phase progression, Neuron49 (2006), 25-39.
18.
SanoT., SmithC.L. and CantorC.R., Immuno-PCR: very sensitive antigen detection by means of specific antibody-DNA conjugates, Science258 (1992), 120-122.
19.
NiemeyerC.M., AdlerM. and WackerR., Immuno-PCR: high sensitivity detection of proteins by nucleic acid amplification, Trends in Biotechnology23 (2005), 208-216.
20.
LevyM., EllingtonA.D. and PaiS., proximity ligation assay, Google Patents, 2007.
21.
SöderbergO., LeuchowiusK.-J., GullbergM., JarviusM., WeibrechtI., LarssonL.-G. and LandegrenU., Characterizing proteins and their interactions in cells and tissues using the in situ proximity ligation assay, Methods45 (2008), 227-232.
22.
BullockS.L. and WallsK.W., Evaluation of some of the parameters of the enzyme-linked immunospecific assay, Journal of Infectious Diseases136 (1977), S279-S285.
23.
VollerA., BartlettA. and BidwellD., Enzyme immunoassays with special reference to ELISA techniques, Journal of Clinical Pathology31 (1978), 507-520.
24.
MirzaeiA., TavoosidanaG., ModarressiM.H., RadA.A., FazeliM.S., ShirkoohiR., Tavakoli-YarakiM. and MadjdZ., Upregulation of circulating cancer stem cell marker, DCLK1 but not Lgr5, in chemoradiotherapy-treated colorectal cancer patients, Tumor Biology (2015), 1-10.
25.
MirzaeiA., TavoosidanaG., RadA.A., RezaeiF., Tavakoli-YarakiM., KadijaniA.A., KhaliliE. and MadjdZ., A new insight into cancer stem cell markers: Could local and circulating cancer stem cell markers correlate in colorectal cancer?Tumor Biology (2015), 1-10.
26.
SobinL.H., GospodarowiczM.K. and WittekindC., TNM Classification of Malignant Tumours, John Wiley & Sons, 2011.
27.
SauerR., LierschT., MerkelS., FietkauR., HohenbergerW., HessC., BeckerH., RaabH.-R., VillanuevaM.-T. and WitzigmannH., Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: Results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years, Journal of Clinical Oncology30 (2012), 1926-1933.
28.
KrugerN.J., The Bradford method for protein quantitation, in: Basic Protein and Peptide Protocols, Springer, 1994, pp. 9-15.
29.
EngvallE. and PerlmannP., Enzyme-linked immunosorbent assay, ELISA III. Quantitation of specific antibodies by enzyme-labeled anti-immunoglobulin in antigen-coated tubes, The Journal of Immunology109 (1972), 129-135.
30.
NiemeyerC.M., AdlerM. and WackerR., Detecting antigens by quantitative immuno-PCR, Nature Protocols2 (2007), 1918-1930.
31.
NongR.Y., WuD., YanJ., HammondM., GuG.J., Kamali-MoghaddamM., LandegrenU. and DarmanisS., Solid-phase proximity ligation assays for individual or parallel protein analyses with readout via real-time PCR or sequencing (vol 8, pg 1234, 2013), Nature Protocols10 (2015), 643-643.
32.
BellowsC.F. and GagliardiG., DCLK1 expression in gastrointestinal stem cells and neoplasia, journal of Cancer Therapeutics and Research1 (2012), 12.
33.
DuL., WangH., HeL., ZhangJ., NiB., WangX., JinH., CahuzacN., MehrpourM. and LuY., CD44 is of functional importance for colorectal cancer stem cells, Clinical Cancer Research14 (2008), 6751-6760.
34.
Ricci-VitianiL., LombardiD.G., PilozziE., BiffoniM., TodaroM., PeschleC. and De MariaR., Identification and expansion of human colon-cancer-initiating cells, Nature445 (2007), 111-115.
35.
BarkerN., van EsJ.H., KuipersJ., KujalaP., van den BornM., CozijnsenM., HaegebarthA., KorvingJ., BegthelH. and PetersP.J., Identification of stem cells in small intestine and colon by marker gene Lgr5, Nature449 (2007), 1003-1007.
36.
GagliardiG., GoswamiM., PasseraR. and BellowsC.F., DCLK1 immunoreactivity in colorectal neoplasia, Clinical and Experimental Gastroenterology5 (2012), 35.
37.
ItoH., TanakaS., AkiyamaY., ShimadaS., AdikrisnaR., MatsumuraS., AiharaA., MitsunoriY., BanD. and OchiaiT., Dominant Expression of DCLK1 in Human Pancreatic Cancer Stem Cells Accelerates Tumor Invasion and Metastasis, PloS One11 (2016).
38.
LeeflangM.M., RutjesA.W., ReitsmaJ.B., HooftL. and BossuytP.M., Variation of a test's sensitivity and specificity with disease prevalence, Canadian Medical Association Journal185 (2013), E537-E544.
39.
DyllaS.J., BevigliaL., ParkI.-K., ChartierC., RavalJ., NganL., PickellK., AguilarJ., LazeticS. and Smith-BerdanS., Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy, PloS One3 (2008), e2428.
40.
RichJ.N. and BaoS., Chemotherapy and cancer stem cells, Cell Stem Cell1 (2007), 353-355.
41.
MirzaeiA., TavoosidanaG., ModarressiM.H., RadA.A., FazeliM.S., ShirkoohiR., Tavakoli-YarakiM. and MadjdZ., Upregulation of circulating cancer stem cell marker, DCLK1 but not Lgr5, in chemoradiotherapy-treated colorectal cancer patients, Tumor Biology36 (2015), 4801-4810.
42.
DeuelT.A., LiuJ.S., CorboJ.C., YooS.-Y., Rorke-AdamsL.B. and WalshC.A., Genetic interactions between doublecortin and doublecortin-like kinase in neuronal migration and axon outgrowth, Neuron49 (2006), 41-53.
43.
OmoriY., SuzukiM., OzakiK., HaradaY., NakamuraY., TakahashiE.-i. and FujiwaraT., Expression and chromosomal localization of KIAA0369, a putative kinase structurally related to Doublecortin, Journal of Human Genetics43 (1998), 169-177.
